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Abstract
Background: The role of the kidney in glucose homeostasis has gained global interest. Kidneys are innervated by
renal nerves, and renal denervation animal models have shown improved glucose regulation. We hypothesized that
stimulation of renal nerves at kilohertz frequencies, which can block propagation of action potentials, would
increase urine glucose excretion. Conversely, we hypothesized that low frequency stimulation, which has been
shown to increase renal nerve activity, would decrease urine glucose excretion.
Methods: We performed non-survival experiments on male rats under thiobutabarbital anesthesia. A cuff electrode
was placed around the left renal artery, encircling the renal nerves. Ureters were cannulated bilaterally to obtain
urine samples from each kidney independently for comparison. Renal nerves were stimulated at kilohertz
frequencies (1–50 kHz) or low frequencies (2–5 Hz), with intravenous administration of a glucose bolus shortly into
the 25–40-min stimulation period. Urine samples were collected at 5–10-min intervals, and colorimetric assays were
used to quantify glucose excretion and concentration between stimulated and non-stimulated kidneys. A Kruskal-
Wallis test was performed across all stimulation frequencies (α = 0.05), followed by a post-hoc Wilcoxon rank sum
test with Bonferroni correction (α = 0.005).
Results: For kilohertz frequency trials, the stimulated kidney yielded a higher average total urine glucose excretion
at 33 kHz (+ 24.5%; n = 9) than 1 kHz (− 5.9%; n = 6) and 50 kHz (+ 2.3%; n = 14). In low frequency stimulation trials,
5 Hz stimulation led to a lower average total urine glucose excretion (− 40.4%; n = 6) than 2 Hz (− 27.2%; n = 5). The
average total urine glucose excretion between 33 kHz and 5 Hz was statistically significant (p < 0.005). Similar
outcomes were observed for urine flow rate, which may suggest an associated response. No trends or statistical
significance were observed for urine glucose concentrations.
Conclusion: To our knowledge, this is the first study to investigate electrical stimulation of renal nerves to
modulate urine glucose excretion. Our experimental results show that stimulation of renal nerves may modulate
urine glucose excretion, however, this response may be associated with urine flow rate. Future work is needed to
examine the underlying mechanisms and identify approaches for enhancing regulation of glucose excretion.
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Background
Diabetes mellitus is a chronic progressive disease that re-
quires continuous monitoring and medical care to prevent
the development of severe complications (American Dia-
betes Association (ADA) 2018). Medications for diabetic
management are numerous and have different mecha-
nisms of action (Chatterjee and Davies 2015). Recently,
sodium-glucose co-transporter 2 (SGLT-2) inhibitors were
approved by the US Food and Drug Administration (FDA)
for patients with type 2 diabetes. SGLT-2 inhibitors pre-
vent the activity of SGLT-2 transporters in the renal prox-
imal tubule, thereby reducing glucose reuptake by the
kidneys and increasing glucose excretion into urine (Lew
and Wick 2015). Despite the progress in the development
of diabetic medications, many lose their effectiveness over
time, which makes achieving blood glucose control targets
difficult for many diabetic patients (Blak et al. 2012;
Khunti et al. 2013; Ali et al. 2013). Furthermore, sustained
patient adherence to these diabetic medications in a life-
long therapy is a major challenge (García-Pérez et al.
2013; Sabaté 2003). Therefore, there is a crucial need for
alternative diabetic therapies that overcome these pharma-
ceutical limitations.
In recent years, a global interest has emerged for
catheter-based renal denervation as a potential treat-
ment for drug-resistant hypertension (Pan et al. 2015;
Bhatt et al. 2014). Early clinical trials of renal denerv-
ation showed significant blood pressure improvements
(Esler et al. 2010; Krum et al. 2009). Interestingly, renal
denervation was also associated with significant de-
creases in blood glucose levels (Mahfoud et al. 2011;
Witkowski et al. 2011). Renal denervation studies in ani-
mals align with the observed blood glucose control im-
provements reported in clinical trials (Rafiq et al. 2015;
Iyer et al. 2016). Furthermore, a recent study reported
that mutant (neuronal POMC-deficient) mice showed
improved capability for tolerating high blood glucose
levels by exaggerating urine glucose excretion (glyco-
suria) compared to wild-type mice at similar induced
blood glucose concentrations (Chhabra et al. 2016). A
following study determined that the observed glycosuria
and improved glucose tolerance were a result of reduced
activity in renal sympathetic nerves (Chhabra et al.
2017). A non-pharmaceutical and reversible approach
that has emerged in recent years for reducing nerve ac-
tivity is kilohertz frequency stimulation, which has dem-
onstrated nerve conduction block on multiple types of
nerves (Kilgore and Bhadra 2014; Joseph and Butera
2009; Joseph and Butera 2011). We hypothesized that
kilohertz frequency stimulation (1–50 kHz) on renal
nerves would attain similar results to renal denervation
and induce urine glucose excretion.
Several studies have successfully influenced renal nerve
activity in humans and animals by applying electrical
stimulation. Electrical stimulation of renal nerves with an
intra-arterial catheter electrode demonstrated increased
blood pressure, and was considered as a method for locat-
ing suitable renal denervation targets for the treatment of
drug-resistant hypertensive patients (Chinushi et al. 2013;
Madhavan et al. 2014; Gal et al. 2015). Direct stimulation
of renal nerves in rats using wire hook electrodes at low
frequencies (0.5–10 Hz) showed increased renin secretion
and water reabsorption, and decreased renal blood flow
and sodium excretion responses (DiBona and Kopp 1997;
DiBona and Sawin 1982; Bello-Reuss et al. 1976; Her-
mansson et al. 1981; Van Vliet et al. 1991). Sodium and
glucose reabsorption are partially associated due to the
presence of sodium-glucose co-transporters (SGLTs) in
the renal proximal tubule (Mather and Pollock 2011). Our
hypothesis was that direct stimulation of renal nerves at
low frequencies (0.5–10 Hz) would decrease urine glucose
excretion.
Therapies that directly alter neural activity (neuromo-
dulation) are commonly prescribed as treatments for a
variety of conditions (Krames et al. 2009; Famm et al.
2013). Gastric electrical stimulation is used to help pa-
tients with delayed stomach-emptying of solid foods
(gastroparesis), which is commonly observed in patients
with diabetes (Abell et al. 2003). Vagal nerve block
(vBloc) therapy was recently approved by the FDA for
certain patients with morbid obesity (Apovian et al.
2017). Clinical trials on vBloc therapy reported improve-
ments in blood glucose control for patients with obesity
and type 2 diabetes but were not sustained after
24 months (Herrera et al. 2017). Despite the success of
neuromodulation therapies, to our knowledge, no clin-
ical studies have investigated organ-targeted neuromo-
dulation as a treatment approach for diabetes. In this
study, we investigated modulation of urine glucose ex-
cretion with kilohertz and low frequency stimulation on
renal nerves.
Methods
All experimental procedures were approved by the Uni-
versity of Michigan Institutional Animal Care and Use
Committee (IACUC).
Animals and housing
Rats have a similar urinary system to humans and rat
renal nerves have been visualized by several research
groups (Stocker and Muntzel 2013; Miki et al. 2002).
Non-survival, anesthetized experiments were performed
on 24 male 290–550 g Long-Evans and Sprague-Dawley
rats (Charles Rivers Laboratories, Wilmington, MA,
USA). All animals were housed in ventilated cages under
controlled temperature, humidity, and photoperiod
(12-h light/dark cycle). The animals were provided with
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laboratory chow (5L0D, LabDiet, St. Louis, MO, USA)
and tap water ad libitum.
Experimental preparation
For anesthesia, a single dose of thiobutabarbital sodium
salt hydrate (Inactin, T133-1G, Sigma-Aldrich Corp., St.
Louis, MO, USA) was injected intraperitoneally (110 mg/
kg BW). Thiobutabarbital is commonly used in renal stud-
ies and is known to preserve renal function during
anesthesia (Walter et al. 1989; Sohtell et al. 1983). Rats
were placed on a heating pad (ReptiTherm, Zoo Med La-
boratories Inc., San Luis Obispo, CA, USA) and
temperature was monitored through a rectal temperature
sensor (SurgiVet, Smiths Medical, Norwell, MA, USA).
Under a dissection microscope (Lynx EVO, Vision Engin-
eering Inc., New Milford, CT, USA), a midline cervical in-
cision was made and the jugular vein was cannulated with
polyethylene tubing (BTPE-50, Instech Laboratories Inc.,
Plymouth Meeting, PA, USA). Through the jugular vein,
0.9% NaCl (saline), equivalent to 10% body weight, was in-
fused over 30 min, and then followed by a continuous in-
fusion of 0.2 mL/min using a syringe pump (NE-1000,
New Era Pump Systems Inc., Farmingdale, NY, USA) (Bel-
lo-Reuss et al. 1976). A tracheotomy was performed to en-
sure a clear airway. Ureters were cannulated bilaterally
with polyethylene tubing (BTPE-10, Instech Laboratories
Inc., Plymouth Meeting, PA, USA) to obtain urine samples
from each kidney independently. The left kidney was ex-
posed through a midline abdominal incision. Fat and con-
nective tissue surrounding the kidney were separated
using cotton-tipped applicators to further expose the kid-
ney and renal artery. A bipolar nerve cuff electrode
(1.00 mm inner-diameter, 100 μm platinum contacts, Mi-
croprobes for Life Science, Gaithersburg, MD, USA) was
placed around the renal artery, encircling renal nerves that
run along the artery (Stocker and Muntzel 2013; Miki et
al. 2002). Care was taken to not damage the renal nerve
branches and to not occlude blood flow in the renal artery.
To ensure that the renal nerves were intact, biphasic
stimulation pulses at 10 Hz, 10 V were applied for ap-
proximately 1 min through the nerve cuff electrode. This
resulted in temporary kidney ischemia, which was con-
firmed by the observation of kidney surface blanching
(Hermansson et al. 1981; Yao et al. 2014). This
stimulation-driven ischemia occurred in all the experi-
ments in which we performed the test (n = 18). Prior to
implant, electrode impedance measurements (4.77 ± 1.53
kΩ) were taken using an impedance tester (nanoZ, White
Matter LLC, Seattle, WA, USA) at 1 kHz in saline to con-
firm functionality of the nerve cuff electrode.
Electrical stimulation
The nerve cuff electrode placed on the renal nerves was
connected to an isolated pulse stimulator (Model 4100,
A-M Systems, Loop Sequim, WA, USA). For kilohertz
frequency stimulation, a function generator (33220A,
Agilent Technologies, Santa Clara, CA, USA) was con-
nected to the isolated pulse stimulator to generate sinus-
oidal waveforms at 1, 33 or 50 kHz. The stimulation
amplitude was fixed at 15 V, which has been shown to
provide nerve conduction block for all selected frequen-
cies on unmyelinated nerves (Joseph and Butera 2009;
Joseph and Butera 2011). For low frequency stimulation,
the isolated pulse stimulator generated biphasic pulses at
2 or 5 Hz. The stimulation amplitude and pulse width
was fixed at 10 V and 0.5 msec, respectively, which is
above the activation threshold for rat C-fibers using cuff
electrodes (Woodbury and Woodbury 1990). The stimu-
lation frequencies were randomly ordered between trials
across all experiments to mitigate sequential effects.
Experimental protocol
After completion of surgery, a stabilization period of
10–60 min was provided. In each experiment, 1–3 trials
with different stimulation frequencies were applied on
the nerve cuff electrode. Stimulation was applied at the
start of a trial and remained on for 25–40 min. To ele-
vate blood glucose levels beyond the expected renal
threshold for glucose excretion (400 mg/dL) (Liang et al.
2012), a 0.30–1.00 g bolus dose of glucose (50% Dex-
trose Injection USP, Hospira Inc., Lake Forest, IL, USA)
was delivered through the jugular vein at 2–16 min into
each trial. To confirm blood glucose increase and to
monitor blood glucose levels over time, drops of blood
(< 0.1 mL) from a tail cut were used to obtain blood glu-
cose concentration measurements using a glucometer
(AlphaTRAK 2, Abbott, Abbott Park, IL, USA) before
glucose infusion and every 5–10 min after glucose infu-
sion. Urine samples from each kidney were collected in
pre-weighed sampling tubes (3448, Thermo Fisher Scien-
tific, Waltham, WA, USA) at 5–10-min intervals. Ten
minutes after the end of a trial, blood glucose measure-
ments were expected to be around baseline levels. If not,
a longer washout period was provided to the rat before
proceeding to the next experimental trial. The collected
urine samples were weighed on a scale (AE 160, Mettler
Toledo, Columbus, OH, USA) for volume estimations
(1 μL/mg). Urine glucose concentrations were measured
using colorimetric assays (10009582, Cayman Chemical,
Ann Arbor, MI, USA). The experimental setup and
protocol timeline are summarized in Fig. 1.
From the urine sample volumes and glucose concen-
tration measurements, the total urine glucose excretion
(UGE) was calculated and compared between the stimu-
lated and non-stimulated kidney [ΔUGE = (UGEstimulated
– UGEnon-stimulated)/UGEnon-stimulated × 100] for each
trial. For urine glucose concentration (UGC) and urine
flow rate (UFR), the area under the curve (AUC) was
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calculated for each trial by trapezoidal numerical inte-
gration and compared between the kidneys in a similar
manner as UGE. From blood glucose concentration
(BGC) values, a BGC decrease rate (BGCDR) was ob-
tained by calculating the linear regression slope of BGC
values starting approximately 10 min after the glucose
c
b
a
Fig. 1 Experimental setup diagram and protocol timeline. a Experimental setup: Jugular vein was cannulated for saline and glucose infusion. Nerve
cuff electrode was placed on renal nerves of the left kidney and connected to a stimulation generator. Ureters were cannulated bilaterally, and urine
samples were collected in sampling vials. b Nerve cuff electrode was placed around the renal artery, encapsulating the renal nerve branches that run
along the renal artery. c Timeline for experimental protocol: Each experiment consisted of 1–3 stimulation trials (T1-T3), with a rest period (R) before
each trial. A glucose bolus was infused in each trial. Blood glucose measurements and urine samples were obtained periodically throughout the trials
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bolus infusion and ending with the final value in the
trial. The glucometer was unable to read blood glucose
concentrations above 750 mg/dL, which occasionally oc-
curred during the first 10 min after a glucose bolus infu-
sion. Therefore, BGC values within 10 min after a
glucose bolus infusion were excluded in BGCDR calcula-
tions for all stimulation trials.
Statistical analysis
Across all experiments, data sets did not follow a normal dis-
tribution (confirmed by one-sample Kolmogorov-Smirnov
test). Therefore, a non-parametric Kruskal-Wallis test was
performed to measure statistical significance across stimula-
tion frequencies. Statistical significance was considered at p
< 0.05. A two-sided Wilcoxon rank sum test was then ap-
plied between pairs of stimulation frequencies. The signifi-
cance level (α) was adjusted according to a Bonferroni
correction, where α was divided by the number of stimula-
tion pairs (10). Thus, statistical significance for the Wilcoxon
rank sum test was considered at p < 0.005. All data analysis
and statistical tests were performed using MATLAB software
(R2014b, MathWorks, Natick, MA, USA).
Results
Across the 24 experiments on male rats, we performed
stimulation trials at kilohertz frequencies (1 kHz [n = 6],
33 kHz [n = 9] and 50 kHz [n = 14]) and low frequencies
(2 Hz [n = 5] and 5 Hz [n = 6]). We obtained measure-
ments of urine glucose excretion, urine glucose concen-
tration, urine flow rate, and blood glucose concentration
in each trial.
Urine glucose excretion
Glucose excretion was analyzed and compared between
the urine samples obtained from the stimulated and
non-stimulated kidneys. The percentage difference of
urine glucose excretion (ΔUGE) between the stimulated
and non-stimulated kidneys for all stimulation frequen-
cies are shown in Fig. 2a. Overall, stimulation frequency
had a statistically significant effect on ΔUGE (Kruskal--
Wallis test, p < 0.05). In kilohertz frequency trials,
33 kHz yielded a higher average ΔUGE (+ 24.5%; n = 9)
than 1 kHz (− 5.9%; n = 6) and 50 kHz (+ 2.3%; n = 14).
In low frequency trials, 5 Hz stimulation led to a lower
average ΔUGE (− 40.4%; n = 6) than 2 Hz (− 27.2%; n =
5). Statistical significance only occurred between the
ΔUGE of 33 kHz and 5 Hz trials (Wilcoxon rank sum
test, p < 0.005). Stimulation at kilohertz frequencies met
our hypothesis of increased UGE in 14 trials (48.2%),
had no apparent effect (|ΔUGE| < 5%) in 10 trials
(34.5%), and showed a decrease in UGE in 5 trials
(17.2%) out of the 29 total kilohertz frequency trials. In
low frequency stimulation trials, we observed a decrease
of UGE in 9 trials (81.8%), no apparent effect in 1 trial
a
b
c
d
Fig. 2 Changes in urine glucose excretion. a The percentage difference in urine glucose excretion between the stimulated and non-stimulated
kidney (ΔUGE) at the applied stimulation frequencies. Stimulation frequency had a statistically significant main effect (Kruskal-Wallis test, p < 0.05),
with one within-frequency comparison being significant (5 Hz and 33 kHz, post-hoc Wilcoxon rank sum test, * = p < 0.005). b Representative
stimulation trial at 33 kHz that showed an increase in UGE. c Representative stimulation trial at 33 kHz that showed no apparent effect on UGE.
d Representative stimulation trial at 33 kHz that showed a decrease in UGE
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(9.1%), and an increase of UGE in 1 trial (9.1%) out of
11 trials in total. Examples of stimulation trials at
33 kHz that displayed an increase, no apparent effect, or
a decrease in UGE are shown in Fig. 2b-d.
Urine glucose concentration
The urine glucose concentration (UGC) differences be-
tween the urine samples obtained from the stimulated and
non-stimulated kidneys at all stimulation frequencies are
shown in Fig. 3a. The average UGC difference was + 5.9%
at 2 Hz (n = 5), + 12.6% at 5 Hz (n = 6), + 3.7% at 1 kHz (n
= 6), + 3.7% at 33 kHz (n = 9), and − 6.2% at 50 kHz (n =
14). Stimulation frequency did not have an overall signifi-
cant effect on UGC (Kruskal-Wallis test, p = 0. 2365).
Urine flow rate
The urine flow rate (UFR) differences between the urine
samples obtained from the stimulated and non-stimulated
kidneys at all stimulation frequencies are shown in
Fig. 4a. The average UFR difference was − 27.7% at
2 Hz (n = 5), − 40.6% at 5 Hz (n = 6), − 6.0% at 1 kHz
(n = 6), + 14.6% at 33 kHz (n = 9), and + 9.8% at
50 kHz (n = 14). Stimulation frequency had a statisti-
cally significant main effect on UFR (Kruskal-Wallis
test, p < 0.05), with trials at 33 kHz and 5 Hz signifi-
cantly different from one another (post-hoc Wilcoxon
rank sum test, p < 0.005).
Blood glucose concentration
The blood glucose concentration decrease rates (BGCDRs)
during stimulation at all frequencies are shown in Fig. 5a.
The average BGCDR was − 9.1 mg/dL/min at 2 Hz (n = 4),
− 13.5 mg/dL/min at 5 Hz (n = 5), − 13.5 mg/dL/min at
1 kHz (n = 6), − 12.0 mg/dL/min at 33 kHz (n = 9), and −
12.5 mg/dL/min at 50 kHz (n = 13). No statistically signifi-
cant main effect occurred across all stimulation frequencies
(Kruskal-Wallis test, p = 0.4708). BGCDR at some stimula-
tion trials [2 Hz (n = 1), 5 Hz (n = 1) and 50 kHz (n = 1)]
were not calculated due to insufficient BGC values.
Discussion
The aim of this study was to investigate modulation of
urine glucose excretion by electrical stimulation of renal
nerves. We hypothesized that stimulation of renal nerves
at kilohertz frequencies (1–50 kHz) would increase urine
glucose excretion (UGE), while low frequency stimu-
lation (2–5 Hz) would decrease UGE. Although
stimulation at kilohertz frequencies did not always
lead to an increase in UGE, 33 kHz showed a not-
able average increase in UGE in accordance with our
hypothesis. In contrast, low frequency stimulation
typically showed a decrease in UGE, with the stron-
gest effect observed at 5 Hz stimulation (Fig. 2). To
our knowledge, this study is the first to demonstrate
influence of electrical stimulation of renal nerves on
glucose excretion.
a
b
c
d
Fig. 3 Changes in urine glucose concentration. a The percentage difference between the area under the curve for urine glucose concentration of the
stimulated and non-stimulated kidney (ΔAUCUGC) at the applied stimulation frequencies. b Urine glucose concentration (UGC) measurements for the
trial shown in Fig. 2b. c UGC measurements for the trial shown in Fig. 2c. d UGC measurements for the trial shown in Fig. 2d
Jiman et al. Bioelectronic Medicine  (2018) 4:7 Page 6 of 11
ab
c
d
Fig. 4 Changes in urine flow rate. a The percentage difference between the area under the curve for urine flow rate of the stimulated and
non-stimulated kidney (ΔAUCUFR) at the applied stimulation frequencies. Stimulation frequency had a significant main effect (Kruskal-Wallis test,
p < 0.05), with 5 Hz and 33 kHz trials significantly different from each other (post-hoc Wilcoxon rank sum test, * = p < 0.005). b Urine flow rate
(UFR) measurements for the trial shown in Fig. 2b. c UFR measurements for the trial shown in Fig. 2c. d UFR measurements for the trial shown
in Fig. 2d
a
b
c
d
Fig. 5 Changes in blood glucose concentration. a The blood glucose concentration decrease rate (BGCDR) at the applied stimulation frequencies.
b Blood glucose concentration (BGC) measurements and BGCDR (slope) for the trial shown in Fig. 2b. c BGC and BGCDR measurements for the
trial shown in Fig. 2c. d BGC and BGCDR measurements for the trial shown in Fig. 2d. BGC measurements above 750 mg/dL were not available
due to the limitations of the glucometer
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The average differences in UGE were similar to the
average differences observed in urine flow rate (UFR), as
shown in Fig. 4. This associated response may suggest
that either UGE or UFR was the primary effect of stimu-
lation, while the other was a secondary response. Previ-
ous studies that applied stimulation of renal nerves at
low frequencies observed a 25–52% reduction in UFR
(Bello-Reuss et al. 1976; Pontes et al. 2015). Those
percentages align with the average reduction of UFR we
observed at low frequency stimulation (28% at 2 Hz,
41% at 5 Hz), suggesting that UFR may be the primary
response of stimulation at low frequencies. On the other
hand, we observed an increase in UFR at 33 and 50 kHz
stimulation. To our knowledge, no studies have reported
an increase in UFR by stimulation of renal nerves.
Although it is possible that changes in UFR may have
directly led to corresponding changes in UGE, the pri-
mary response of UFR or UGE to stimulation at kilo-
hertz frequencies cannot be determined in this study.
UFR and UGE are normally associated, as increased
urination is a common adverse event in diabetic patients
treated with sodium-glucose co-transporter 2 (SGLT2)
inhibitors that primarily increase urine glucose excretion
(Seufert 2015; Wilding 2014). Additional studies are re-
quired to distinguish the glucose excretion and urine
flow effects for stimulation of renal nerves.
Stimulation of renal nerves did not have a clear effect
on urine glucose concentration (UGC), as no statistical
significance occurred across stimulation frequencies
(Fig. 3). Furthermore, we did not observe a clear differ-
ence between kilohertz or low frequency stimulation on
the decrease rate for blood glucose concentration (BGC)
after infusion of a glucose bolus (Fig. 5). Typically, BGC
would reach a peak value within the first 10 min after
glucose bolus infusion. Then, BGC values would grad-
ually decrease and return to around baseline values at
30–40 min after the glucose infusion, regardless of the
stimulation parameters. The variation in the sample size
of the stimulation frequency groups may have also con-
tributed to these unclear responses. Modifications and
improvements in experimental design may be necessary
to capture clear and consistent responses to stimulation
of renal nerves.
Renal nerve branches are distributed around the renal
artery in a plexus form. Ultrastructural studies using
electron microscopy techniques have shown that renal
nerve fibers innervate epithelial cells of proximal tu-
bules, the glucose reabsorption region of the kidney
(Mather and Pollock 2011; Muller and Barajas 1972; Luff
et al. 1992). Although studies have examined the distri-
bution of renal nerves around the renal artery (Maeda et
al. 2014; Sakakura et al. 2014; van Amsterdam et al.
2016), we could not determine the renal nerve branches
that innervate the proximal tubules in this study.
Therefore, we utilized a cuff electrode with the purpose
of encircling all the renal nerve branches surrounding
the renal artery. In order to place a cuff electrode, the
renal artery was isolated by removing adjacent connect-
ive tissue that may have contained fine renal nerve
branches. Although we ensured that the renal nerves were
moderately intact by observing temporary kidney surface
blanching at 10 Hz stimulation (Hermansson et al. 1981;
Yao et al. 2014), the variations in connective tissue re-
moval and relative shifts in the electrode placement along
the renal artery across experiments may have contributed
to the variability of our outcome results. This inconsist-
ency in outcomes has also been observed in renal denerv-
ation studies, where conflicting results were reported in
clinical studies (Bhatt et al. 2014; Mahfoud et al. 2011;
Witkowski et al. 2011). The reported variability is sus-
pected to be from variations in ablation locations across
renal denervation procedures performed in multiple cen-
ters (Mahfoud et al. 2014). Experimental improvements in
electrode placement and the plexus-electrode interface
may be required to obtain more consistent results.
An anatomical analysis in rats showed that 96% of
renal nerve axons are unmyelinated C-fibers (DiBona et
al. 1996). Although nerve conduction block experiments
using kilohertz frequency stimulation have been typically
performed using cuff electrodes encircling myelinated
motor neurons while monitoring muscle tension for
block validation (Kilgore and Bhadra 2014; Bhadra and
Kilgore 2005), nerve block has also been demonstrated
on purely unmyelinated fibers using suction electrodes
and confirmed by direct recordings of action potential
propagation (Joseph and Butera 2009). In this study, the
amplitude of sinusoidal kilohertz frequency stimulation
was fixed at 15 V, which is expected to be above the
threshold for nerve conduction block at the selected fre-
quencies (Joseph and Butera 2011; Bhadra and Kilgore
2005; Patel and Butera 2015). On the other hand, previ-
ous studies increased renal nerve activity by low fre-
quency stimulation (Bello-Reuss et al. 1976; DiBona
2000). The stimulation amplitude and pulse width in this
study at low frequencies was consistent at 10 V and
0.5 msec, respectively, which is above the activation
threshold for rat C-fibers using cuff electrodes (Wood-
bury and Woodbury 1990). However, to validate the true
presence of nerve conduction block or increased neural
activity, multiple recording and stimulating electrodes
must be placed along the renal nerves. Unfortunately,
this was difficult to accomplish in this study due to our
limited ability to expose and isolate the renal nerves (~
2–4 mm), in addition to the anticipated noise contamin-
ation issues between adjacent stimulating and recording
electrodes (Kilgore and Bhadra 2014). Additional experi-
ments are required to examine the mechanism of action
for stimulation of renal nerves.
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The work presented here was a feasibility study to in-
vestigate glucose excretion modulation by stimulation of
renal nerves. There are numerous limitations to this
study. Although changes in UGE were observed in
response to stimulation of renal nerves, this study does
not provide any evidence on the underlying mechanisms
for these changes. It is unknown if the observed changes
in UGE were a consequence of changes in UFR, or
directly related to the gluconeogenesis process or the
glucose transport pathways in the proximal tubules that
are innervated by renal nerves (Mather and Pollock
2011; Muller and Barajas 1972; Luff et al. 1992).
Measurements of renal function, such as glomerular fil-
tration rate, renal plasma flow and sodium excretion
(Toto 1995; Phillips and Hamilton 1948) were not
obtained in this feasibility study. The assessment of renal
function is an absolute necessity for the progression of
this research. The large variation in the results of this
study may have been due to multiple reasons. In
addition to the variability in electrode placement, the uni-
lateral stimulation approach in this study may have pro-
voked reno-renal reflexes, where the non-stimulated
kidney modifies its activity based on changes in the stimu-
lated kidney (Zanchetti et al. 1984). The possible presence
of these reflexes may have altered the outcomes of this
study. Further experiments with reno-renal reflex elimin-
ation procedures, such as bilateral stimulation or denerv-
ation of non-stimulated kidneys, may be necessary to
obtain unhindered stimulation outcomes.
Although further experiments are required to examine
the underlying mechanisms for stimulation of renal
nerves, this study may introduce a new approach for regu-
lation of glucose excretion. Recently approved medications
for patients with type 2 diabetes are SGLT-2 inhibitors,
which prevent the activity of glucose transporters in the
kidney and lead to increased glucose excretion into urine
(Lew and Wick 2015). Stimulation of renal nerves may
provide an alternative treatment approach for glycemic
control that avoids patient compliance issues typically
seen with medications (Polonsky and Henry 2016).
Conclusion
To our knowledge, this is the first study to investigate
electrical stimulation of renal nerves to modulate urine
glucose excretion. Our experimental results show that
stimulation of renal nerves may modulate urine glucose
excretion, however, this outcome may be associated with
urine flow rate. Future work is needed to examine the
underlying mechanisms and identify approaches for en-
hancing regulation of glucose excretion.
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